Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04473378 · ClinicalTrials.gov registry record
Glucose Monitoring During Chemotherapy
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 22
- Enrollment target
NCT04473378: Completed study, sponsored by Columbia University.
NCT04473378 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04473378 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
This is a research study to look at blood sugar changes during chemotherapy using a continuous blood sugar monitoring device. The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course. Each patch lasts for about 2-weeks. During chemotherapy visits, new patches will be placed and will be worn until the chemotherapy course is complete. Participants will be in this study for 6 months. Approximately 50 patients will be enrolled in this study.
Primary Outcome
assess the prevalence of HG, defined as the number of participants who have ≥1 glucose value of ≥140 mg/dL at any point during chemotherapy
Interventions
- DEVICE FreeStyle Libre Pro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2022-08-17 |
What the finished NCT04473378 record still lists
NCT04473378 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which FreeStyle Libre Pro is the first listed.
NCT04473378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04473378 about?
NCT04473378 is a clinical study titled "Glucose Monitoring During Chemotherapy". This is a research study to look at blood sugar changes during chemotherapy using a continuous blood sugar monitoring device. The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course. Each patch lasts for about ...
What is the current status of trial NCT04473378?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2019-10-31. Estimated completion is 2022-08-17.
What interventions are being tested in trial NCT04473378?
The interventions under investigation include: FreeStyle Libre Pro (DEVICE).
Who is sponsoring clinical trial NCT04473378?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI